

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) EP 0 923 953 A2

(12) EUROPEAN PATENT APPLICATION

(43) Date of publication:
23.06.1999 Bulletin 1999/25

(51) Int. Cl.⁶: A61L 31/00

(21) Application number: 98202050.5

(22) Date of filing: 19.06.1998

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• Ding, Ni
Plymouth, Minnesota 55446 (US)
• Helmus, Michael N.
Long Beach, California 90807 (US)

(30) Priority: 22.12.1997 US 996410

(74) Representative: Jansen, Götz
Schneider (Europe) GmbH,
Ackerstrasse 6
8180 Bülach (CH)

(71) Applicant: SCHNEIDER (USA) INC.
Plymouth, Minnesota 55442 (US)

(54) Drug coating with topcoat

(57) A coating and method for a coating an implantable device or prostheses are disclosed. The coating includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein. The coating further includes a topcoat which covers less than the entire surface of the undercoat and wherein the topcoat comprises a poly-

meric material substantially free of pores and porogens. The polymeric material of the topcoat can be a biostable, biocompatible material which provides long term non-thrombogenicity to the device portion during and after release of the biologically active material.




FIG. 9

EP 0 923 953 A2

Description

BACKGROUND OF THE INVENTION

Cross-Reference to Related Applications

[0001] The present application is a Continuation-In-Part of co-pending application 08/663,518, filed June 13, 1996.

Field of the Invention

[0002] The present invention relates generally to providing biostable elastomeric coatings on the surfaces of implants which incorporate biologically active species having controlled release characteristics in the coating and relates particularly to providing a non-thrombogenic surface during and after timed release of the biologically active species. The invention is particularly described in terms of coatings on therapeutic expandable stent prostheses for implantation in body lumens, *e.g.*, vascular implantation.

Related Art

[0003] In surgical or other related invasive procedures, the insertion and expansion of stent devices in blood vessels, urinary tracts or other locations difficult to otherwise access for the purpose of preventing restenosis, providing vessel or lumen wall support or reinforcement and for other therapeutic or restorative functions has become a common form of long-term treatment. Typically, such prostheses are applied to a location of interest utilizing a vascular catheter, or similar transluminal device, to carry the stent to the location of interest where it is thereafter released to expand or be expanded in situ. These devices are generally designed as permanent implants which may become incorporated in the vascular or other tissue which they contact at implantation.

[0004] One type of self-expanding stent has a flexible tubular body formed of several individual flexible thread elements each of which extends in a helix configuration with the centerline of the body serving as a common axis. The elements are wound in the same direction but are displaced axially relative to each other and meet, under crossing a like number of elements also so axially displaced, but having the opposite direction of winding. This configuration provides a resilient braided tubular structure which assumes stable dimensions upon relaxation. Axial tension produces elongation and corresponding diameter contraction that allows the stent to be mounted on a catheter device and conveyed through the vascular system as a narrow elongated device. Once tension is relaxed in situ, the device at least substantially reverts to its original shape. Prostheses of the class including a braided flexible tubular body are illustrated and described in U.S. Patents 4,655,771 and

4,954,126 to Wallsten and 5,061,275 to Wallsten *et al.*

[0005] Implanted stents have been used to carry medicinal agents, such as thrombolytic agents. U.S. Patent 5,163,952 to Froix discloses a thermal-memorized expanding plastic stent device formulated to carry a medicinal agent in the material of the stent itself. Pinchuk, in U.S. Patent 5,092,877, discloses a stent of a polymeric material which may have a coating associated with the delivery of drugs. Other patents which are directed to devices of the class utilizing bio-degradable or bio-sorbable polymers include Tang *et al.*, U.S. Patent 4,916,193, and MacGregor, U.S. Patent 4,994,071.

[0006] A patent to Sahatjian, Patent No. 5,304,121, discloses a coating applied to a stent consisting of a hydrogel polymer and a preselected drug such as a cell growth inhibitors or heparin. A further method of making a coated intravascular stent carrying a therapeutic material is described in Berg *et al.*, U.S. Patent No. 5,464,650, issued on November 7, 1995 and corresponding to European Patent Application No. 0 623 354 A1 published 09 November 1994. In that disclosure, a polymer coating material is dissolved in a solvent and the therapeutic material dispersed in the solvent; the solvent evaporated after application.

[0007] An article by Michael N. Helmus (a co-inventor of the present invention) entitled "Medical Device Design--A Systems Approach: Central Venous Catheters", 22nd International Society for the Advancement of Material and Process Engineering Technical Conference (1990) relates to polymer/drug/membrane systems for releasing heparin. Those polymer/drug/membrane systems require two distinct types of layers to function.

[0008] It has been recognized that contacting blood with the surface of a foreign body in vivo has a tendency to induce thrombogenic responses and that as the surface area of a foreign device in contact with host blood increases, the tendency for coagulation and clot forming at these surfaces also increases. This has led to the use of immobilized systemic anti-coagulant or thrombolytic agents such as heparin on blood contacting surfaces such as oxygen uptake devices to reduce this phenomenon. Such an approach is described by Winters, *et al.*, in U.S. Patents 5,182,317; 5,262,451 and 5,338,770 in which the amine functional groups of the active material are covalently bonded using polyethylene oxide (PEO) on a siloxane surface.

[0009] Another approach is described in U.S. Patent 4,613,665 to Larm in which heparin is chemically covalently bound to plastic surface materials containing primary amino groups to impart a non-thrombogenic surface to the material. Other approaches for bonding heparin are described in Barbucci, *et al.*, "Coating of commercially available materials with a new heparinizable material", *Journal of Biomedical Materials Research*, Vol. 25, pp. 1259-1274 (1991); Hubbell, J.A., "Pharmacologic Modification of Materials", *Cardiovascular Pathology*, Vol. 2, No. 3 (Suppl.), 121S-127S

(1993); Gravlee, G.P., "Heparin-Coated Cardiopulmonary Bypass Circuits", Journal of Cardiothoracic and Vascular Anesthesia, Vol. 8, No. 2, pp. 213-222 (1994).

[0010] Moreover, drug elution rates for a coating containing a hydrophilic or a lipophobic drug is usually very fast initially when the coated device contacts body fluid or blood. One of the methods to reduce the so called "burst effect" is to add a membrane containing porosigen over the coating layer containing the biologically active material. See e.g., U.S. Patent No. 5,605,696 to Eury *et al.* and U.S. Patent No. to Helmus *et al.* 5,447,724. When the porosigen elutes, a porous membrane is formed and the drug in the undercoat will release. Even though the method might be quite successful to control the drug release, it increases the coating thickness, reduces the effective drug loading and introduces undesirable additional foreign materials into the patient. Hence, there is a need for a coating which reduces the burst effect but is not too thick and does not require the release of porosigens into the body.

[0011] With regard to stents, polymeric stents, although effective, may have mechanical properties that are inferior to those of metal stents of like thickness and weave. Metallic vascular stents braided of even relatively fine metal can provide a large amount of strength to resist inwardly directed circumferential pressure. A polymer material of comparable strength requires a much thicker-walled structure or heavier, denser filament weave, which in turn, reduces the cross-sectional area available for flow through the stent and/or reduces the relative amount of open space in the weave. Also, it is usually more difficult to load and deliver polymeric stents using catheter delivery systems.

[0012] While certain types of stents such as braided metal stents may be preferred for some applications, the coating and coating modification process of the present invention is not so limited and can be used on a wide variety of prosthetic devices. Thus, in the case of stents, the present invention also applies, for example, to the class of stents that are not self-expanding; including those which can be expanded, for instance, with a balloon; as well as polymeric stents of all kinds. Other medical devices that can benefit from the present invention include blood exchanging devices, vascular access ports, central venous catheters, cardiovascular catheters, extracorporeal circuits, vascular grafts, pumps, heart valves, and cardiovascular sutures, to name a few. Regardless of detailed embodiments, applicability of the invention should not be considered limited with respect to implant design, implant location or materials of construction. Further, the present invention may be used with other types of implantable prostheses.

[0013] Accordingly, it is a primary object of the present invention to provide a coating and process for coating a stent to be used as a deployed stent prostheses, the coating being capable of effective controlled long-term delivery of biologically active materials.

[0014] Another object of the invention is to provide a

coating and process for coating a stent prostheses using a biostable hydrophobic elastomer in which biologically active species are incorporated within a coating.

[0015] Still another object of the present invention is to provide a multi-layer coating and process for the delivery of biologically active species in which the percentage of active material can vary from layer to layer.

[0016] Yet another object of the present invention is to provide a multi-layer coating and process for the delivery of biologically active species from a coating with a non-thrombogenic surface.

[0017] Another object of the invention is to provide a coating for the delivery of biologically active species having a top layer or topcoat which reduces the initial release of the species, in which the topcoat is substantially free of pores or porosigens and covers less than the entire surface of the undercoat. The topcoat can cover less than the entire surface of the undercoat before and/or while the device is implanted.

[0018] A further object of the invention is to provide a multilayer coating for the delivery of biologically active species such as heparin having a fluorosilicone top layer.

[0019] A still further object of the invention is to provide a multi-layer coating for the delivery of biologically active species such as heparin having a surface containing immobilized polyethylene glycol (PEG).

[0020] Other objects and advantages of the present invention will become apparent to those skilled in the art upon familiarization with the specification and appended claims.

SUMMARY OF THE INVENTION

[0021] The present invention provides a relatively thin layered coating of biostable elastomeric material containing an amount of biologically active material dispersed therein in combination with a non-thrombogenic surface that is useful for coating the surfaces of prostheses such as deployable stents.

[0022] The preferred stent to be coated is a self-expanding, open-ended tubular stent prostheses. Although other materials, including polymer materials, can be used, in the preferred embodiment, the tubular body is formed of a self expanding open braid of fine single or polyfilament metal wire which flexes without collapsing, readily axially deforms to an elongate shape for transluminal insertion via a vascular catheter and resiliently expands toward predetermined stable dimensions upon removal in situ.

[0023] In the process, the initial coating is preferably applied as a mixture, solution or suspension of polymeric material and finely divided biologically active species dispersed in an organic vehicle or a solution or partial solution of such species in a solvent or vehicle for the polymer and/or biologically active species. For the purpose of this application, the term "finely divided"

means any type or size of included material from dissolved molecules through suspensions colloids and particulate mixtures. The biologically active material is dispersed in a carrier material which may be the polymer, a solvent, or both. The coating is preferably applied as a plurality of relatively thin layers sequentially applied in relatively rapid sequence and is preferably applied with the stent in a radially expanded state.

[0024] In many applications the layered coating is referred to or characterized as including an undercoat and topcoat. The coating thickness ratio of the topcoat to undercoat may vary with the desired effect and/or the elution system. Typically these are of different formulations with most or all of the biologically active material being contained in the undercoat and a non-thrombogenic or biocompatible non-porous surface found in the topcoat.

[0025] It is desirable that the topcoat be substantially free of connected pores or porosigens (materials which can elute during implantation and form pores). The addition of a porous membrane as a top coat will increase the coating thickness and reduce the overall drug loading. Also, the release of porosigens into the body can be undesirable since it introduces additional foreign materials into the body, which can cause the patient to have adverse reactions.

[0026] Since in some embodiments the topcoat should be substantially free of pores, the topcoat should cover less than the entire surface of the undercoat. Preferably, the topcoat should cover only about 10% to about 95% of the surface of the undercoat.

[0027] By partially covering the surface during manufacture or inducing "breaks" in the topcoat during mounting/implanting of the coated device, the biologically active material or drug of the undercoat is permitted to be released from the undercoat through those parts of the undercoat which are not covered by the topcoat.

[0028] This mechanism is illustrated by FIGURE 9, which shows a surface of a prosthesis 101 covered by a coating 102 comprising an undercoat 103 and a topcoat 104. The topcoat 104, which only partially covers the undercoat 103, leaves certain areas 106 of the undercoat, including drug particles 105, exposed to body fluids at the implantation site. It is through these "uncovered" areas 106 of the undercoat that the drug particles 105 of the undercoat 103 are allowed to be released into the implantation site.

[0029] Additionally, it is preferred that the topcoats have an average thickness equivalent to the average particle size of the drug in the undercoat. Preferably the average thickness is about 1 to 7 microns and more preferable that the topcoat average thickness be about 1 to 5 microns. Also, the polymer of the topcoat may be the same as or different from the polymer of the undercoat.

[0030] The coating may be applied by dipping or spraying using evaporative solvent materials of rela-

tively high vapor pressure to produce the desired viscosity and quickly establish coating layer thicknesses. The preferred process is predicated on reciprocally spray coating a rotating radially expanded stent employing an air brush device. The coating process enables the material to adherently conform to and cover the entire surface of the filaments of the open structure of the stent but in a manner such that the open lattice nature of the structure of the braid or other pattern is preserved in the coated device.

[0031] The coating is exposed to room temperature ventilation for a predetermined time (possibly one hour or more) for solvent vehicle evaporation. In the case of certain undercoat materials, thereafter the polymer material is cured at room temperature or elevated temperatures. Curing is defined as the process of converting the elastomeric or polymeric material into the finished or useful state by the application of heat and/or chemical agents which induce physico-chemical changes. Where, for example, polyurethane thermoplastic elastomers are used as an undercoat material, solvent evaporation can occur at room temperature rendering the undercoat useful for controlled drug release without further curing.

[0032] The applicable ventilation time and temperature for cure are determined by the particular polymer involved and particular drugs used. For example, silicone or polysiloxane materials (such as polydimethylsiloxane) have been used successfully. Urethane prepolymers can also be utilized. Unlike the polyurethane thermoplastic elastomers, some of these materials are applied as prepolymers in the coating composition and must thereafter be heat cured. The preferred silicone species have a relatively low cure temperatures and are known as a room temperature vulcanizable (RTV) materials. Some polydimethylsiloxane materials can be cured, for example, by exposure to air at about 90°C for a period of time such as 16 hours. A curing step may be implemented both after application of the undercoat or a certain number of lower layers and the top layers or a single curing step used after coating is completed.

[0033] The coated stents may thereafter be subjected to a postcure process which includes an inert gas plasma treatment, and sterilization which may include gamma radiation, ETO treatment, electron beam or steam treatment.

[0034] In the plasma treatment, unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment. One method uses argon (Ar) gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to about 100 - 450 mTorr, and an exposure time from 30 seconds to about 5 minutes. The stents can be removed immediately after the plasma treatment or

remain in the argon atmosphere for an additional period of time, typically five minutes.

[0035] In accordance with the invention, the topcoat or surface coating may be applied in any of several ways to further control thrombolytic effects and optionally, control the release profile especially the initial very high release rate associated with the elution of heparin.

[0036] In one embodiment, an outer layer of fluorosilicone (FSi) is applied to the undercoat as a topcoat. The outer layer can also contain heparin. In another embodiment, polyethylene glycol (PEG) is immobilized on the surface of the coating. In this process, the underlayer is subjected to inert gas plasma treatment and immediately thereafter is treated by ammonia (NH₃) plasma to aminate the surface. Amination, as used in this application, means creating mostly imino groups and other nitro containing species on the surface. This is followed by immediate immersion into electrophilically activated polyethylene glycol (PEG) solution with a reductive agent, i.e., sodium cyanoborohydride.

[0037] To form a topcoat which is substantially free of pores, porosigens or materials capable of eluting from the topcoat during implantation, should not be included in the composition used to form the topcoat. For example, a substantially non-porous topcoat can be produced from a topcoat composition which comprises a substantially pure polymeric material. The material preferably provides biocompatibility to the implanted device during and after release of the biologically active material.

[0038] To prepare a topcoat which covers less than the entire surface of the undercoat, a number of methods can be used. For instance, by controlling the thickness of the topcoat so that it has an average thickness less than that of the diameter of certain drug particles, the undercoat will be only partly covered by the topcoat since some of drug particles will not be covered by the topcoat.

[0039] Also, a partial topcoat can be formed by using a topcoat polymer which is incompatible with the undercoat polymer to generate a microphase separation in the topcoat. Furthermore, to make a topcoat which covers less than the entire surface of the undercoat or which only partially covers the undercoat, a poor solvent wash can be applied to the topcoat, to force the topcoat polymer to shrink so that the undercoat is not entirely covered.

[0040] In other embodiments the topcoat can partially or fully cover the undercoat prior to delivery or implantation of the device. The topcoat materials can be selected so they have certain water permeability. When water penetrates the topcoat and into the drug particles of the undercoat, the water will swell the particles or dissolve the particles. In either situation, it creates osmotic pressure in the surrounding coating material of the undercoat. The pressure then breaks the thinnest part of the topcoat, and leave the void space in the topcoat for the drug to elute out.

[0041] In another embodiment, the topcoat material has a different Young's modulus (either while it is wet or dry) than that of the undercoat material. More specifically, the Young's modulus can be higher for the topcoat material. During the mounting of the coated devices onto the delivery device or during deployment of the coated device, the coating undergoes compression or stretching. Topcoat materials with higher Young's modulus tend to crack and form void spaces for the drug to elute from undercoat.

[0042] Another way to form a topcoat is to cover the undercoat with a bioabsorbable material. In this embodiment, the topcoat can cover either the entire undercoat or only part of the undercoat before or after implantation. Upon contact with body fluids, the bioabsorbable material of the topcoat will degrade. The rate of degradation depends upon the bioabsorbable material used. When the topcoat is partially absorbed, the undercoat is exposed to the body fluid and the drug is released, however the burst effect will be reduced.

[0043] The coated and cured stents having the modified outer layer or surface optionally are subjected to a final gamma radiation sterilization nominally at 2.5-3.5 Mrad. Argon (Ar) plasma treated stents enjoy full resiliency after radiation whether exposed in a constrained or non-constrained status, while constrained stents subjected to gamma sterilization without Ar plasma pretreatment lose resiliency and do not recover at a sufficient or appropriate rate where the undercoat is silicone.

[0044] The elastomeric materials that form the stent coating underlayers should possess certain properties. Preferably the layers should be of suitable hydrophobic biostable elastomeric materials which do not degrade. Surface layer or topcoat materials should minimize tissue rejection and tissue inflammation and permit encapsulation by tissue adjacent the stent implantation site. Exposed material is designed to reduce clotting tendencies in blood contacted and the surface is preferably modified accordingly. Thus, underlayers of the above materials are preferably provided with a silicone or a fluorosilicone outer coating layer which should not contain imbedded bioactive material, such as heparin in order to avoid the formation of pores in the topcoat. Alternatively, the outer coating may consist essentially of polyethylene glycol (PEG), polysaccharides, phospholipids, or combinations of the foregoing.

[0045] Polymers generally suitable for the undercoats or underlayers include silicones (e.g., polysiloxanes and substituted polysiloxanes), polyurethanes, thermoplastic elastomers in general, ethylene vinyl acetate copolymers, polyolefin elastomers, polyamide elastomers, and EPDM rubbers. The above-referenced materials are considered hydrophobic with respect to the contemplated environment of the invention. Surface layer or topcoat materials can include the same polymer as that of the undercoat. Examples of suitable polymers include without limitation fluorosilicones and polyethylene glycol

(PEG), polysaccharides, phospholipids, and combinations of the foregoing.

[0046] While heparin is preferred as the incorporated active material, agents possibly suitable for incorporation include antithrombotics, anticoagulants, antibiotics, antiplatelet agents, thrombolytics, antiproliferatives, steroidal and nonsteroidal antiinflammatories, agents that inhibit hyperplasia and in particular restenosis, smooth muscle cell inhibitors, growth factors, growth factor inhibitors, cell adhesion inhibitors, cell adhesion promoters and drugs that may enhance the formation of healthy neointimal tissue, including endothelial cell regeneration. The positive action may come from inhibiting particular cells (e.g., smooth muscle cells) or tissue formation (e.g., fibromuscular tissue) while encouraging different cell migration (e.g., endothelium) and tissue formation (neointimal tissue).

[0047] Suitable materials for fabricating the braided stent include stainless steel, tantalum, titanium alloys including nitinol (a nickel titanium, thermomemorial alloy material), and certain cobalt alloys including cobalt-chromium-nickel alloys such as Elgiloy[®] and Phynox[®]. Further details concerning the fabrication and details of other aspects of the stents themselves, may be gleaned from the above referenced U.S. Patents 4,655,771 and 4,954,126 to Wallsten and 5,061,275 to Wallsten *et al.*, which are incorporated by reference herein.

[0048] Various combinations of polymer coating materials can be coordinated with biologically active species of interest to produce desired effects when coated on stents to be implanted in accordance with the invention. Loadings of therapeutic materials may vary. The mechanism of incorporation of the biologically active species into the surface coating, and egress mechanism depend both on the nature of the surface coating polymer and the material to be incorporated. The mechanism of release also depends on the mode of incorporation. The material may elute via interparticle paths or be administered via transport or diffusion through the encapsulating material itself.

[0049] For the purposes of this specification, "elution" is defined as any process of release that involves extraction or release by direct contact of the material with bodily fluids through the interparticle paths connected with the exterior of the coating. "Transport" or "diffusion" are defined to include a mechanism of release in which the material released traverses through another material.

[0050] The desired release rate profile can be tailored by varying the coating thickness, the radial distribution (layer to layer) of bioactive materials, the mixing method, the amount of bioactive material, the combination of different matrix polymer materials at different layers, and the crosslink density of the polymeric material. The crosslink density is related to the amount of crosslinking which takes place and also the relative tightness of the matrix created by the particular

crosslinking agent used. This, during the curing process, determines the amount of crosslinking and so the crosslink density of the polymer material. For bioactive materials released from the crosslinked matrix, such as heparin, a denser crosslink structure will result in a longer release time and reduced burst effect.

[0051] It will also be appreciated that an unmedicated silicone thin top layer provides some advantage and additional control over drug elution.

BRIEF DESCRIPTION OF THE DRAWINGS

[0052] In the drawings, wherein like numerals designate like parts throughout the same:

FIGURE 1 is a schematic flow diagram illustrating the steps of the process of the invention;

FIGURE 2 represents a release profile for a multi-layer system showing the percentage of heparin released over a two-week period;

FIGURE 3 represents a release profile for a multi-layer system showing the relative release rate of heparin over a two-week period;

FIGURE 4 illustrates a profile of release kinetics for different drug loadings at similar coating thicknesses illustrating the release of heparin over a two-week period without associated means to provide a long term non-thrombogenic surface thereafter;

FIGURE 5 illustrates drug elution kinetics at a given loading of heparin over a two-week period at different coating thicknesses without associated means to provide a long term non-thrombogenic surface thereafter;

FIGURE 6 illustrates the release kinetics for a given undercoat and topcoat material varied according to thickness in which the percentage heparin in the undercoat and topcoats are kept constant;

FIGURE 7 is a plot of heparin release kinetics in phosphate buffer system at pH 7.4 with and without fluorosilicone (FSi) topcoat; and

FIGURE 8 is another plot of heparin release kinetics in phosphate buffer system in which a topcoat containing fluorosilicone (FSi) only is compared with an FSi topcoat containing 16.7% imbedded heparin.

FIGURE 9 illustrates a surface of an implantable prosthesis covered with an undercoat, containing a biologically active material, which is partly covered by a topcoat.

DETAILED DESCRIPTION

[0053] According to the present invention, the stent coatings incorporating biologically active materials for timed delivery in situ in a body lumen of interest are preferably sprayed in many thin layers from prepared coating solutions or suspensions. The steps of the proc-

ess are illustrated generally in FIGURE 1. The coating solutions or suspensions are prepared at 10 as will be described later. The desired amount of crosslinking agent (if any) is added to the suspension/solution as at 12 and material is then agitated or stirred to produce a homogenous coating composition at 14 which is thereafter transferred to an application container or device which may be a container for spray painting at 16. Typical exemplary preparations of coating solutions that were used for heparin and dexamethasone appear next.

General Preparation of Heparin Undercoating Composition

[0054] Silicone was obtained as a polymer precursor in solvent (xylene) mixture. For example, a 35% solid silicone weight content in xylene was procured from Applied Silicone, Part #40,000. First, the silicone-xylene mixture was weighed. The solid silicone content was determined according to the vendor's analysis. Pre-calculated amounts of finely divided heparin (2-6 microns) were added into the silicone, then tetrahydrofuran (THF) HPCL grade (Aldrich or EM) was added. For a 37.5% heparin coating, having 35% solids, $W_{\text{silicone}} = 5 \text{ g}$ and $W_{\text{hep}} = 5 \times 0.35 \times .375 / (0.625) = 1.05 \text{ g}$ were used. The amount of THF needed (44 ml) in the coating solution was calculated by using the equation $W_{\text{silicone solid}} / V_{\text{THF}} = 0.04$ for a 37.5% heparin coating solution. Finally, the manufacturer crosslinker solution was added by using Pasteur P-pipet. The amount of crosslinker added was formed to effect the release rate profile. Typically, five drops of crosslinker solution were added for each five grams of silicone-xylene mixture. The solution was stirred by using the stirring rod until the suspension was homogenous and milk-like. The coating solution was then transferred into a paint jar in condition for application by air brush.

General Preparation of Dexamethasone Undercoating Composition

[0055] Silicone (35% solution as above) was weighed into a beaker on a Mettler balance. The weight of dexamethasone free alcohol or acetate form was calculated by silicone weight multiplied by 0.35 and the desired percentage of dexamethasone (1 to 40%) and the required amount was then weighed. Example: $W_{\text{silicone}} = 5 \text{ g}$; for a 10% dexamethasone coating, $W_{\text{dex}} = 5 \times 0.35 \times 0.1 / 0.9 = 0.194 \text{ g}$ and THF needed in the coating solution and $W_{\text{silicone solid}} / V_{\text{THF}} = 0.06$ for a 10% dexamethasone coating solution. Example: $W_{\text{silicone}} = 5 \text{ g}$; $V_{\text{THF}} = 5 \times 0.35 / 0.06 \approx 29 \text{ ml}$. The dexamethasone was weighed in a beaker on an analytical balance and half the total amount of THF was added. The solution was stirred well to ensure full dissolution of the dexamethasone. The stirred DEX-THF solution was then transferred to the silicone container. The beaker was washed with the remaining THF and this was transferred to the

silicone container. The crosslinker was added by using a Pasteur pipet. Typically, five drops of crosslinker were used for five grams of silicone.

[0056] The application of the coating material to the stent was quite similar for all of the materials and the same for the heparin and dexamethasone suspensions prepared as in the above Examples. The suspension to be applied was transferred to an application device, at 16 in FIGURE 1. Typically a paint jar attached to an air brush, such as a Badger Model 150, supplied with a source of pressurized air through a regulator (Norgren, 0-160 psi) was used. Once the brush hose was attached to the source of compressed air downstream of the regulator, the air was applied. The pressure was adjusted to approximately 15-25 psi and the nozzle condition checked by depressing the trigger.

[0057] To secure the stent for spraying and rotating fixtures were utilized successfully in the laboratory. Both ends of the relaxed stent were fastened to the fixture by two resilient retainers, commonly alligator clips, with the distance between the clips adjusted so that the stent remained in a relaxed, unstretched condition. The rotor was then energized and the spin speed adjusted to the desired coating speed, nominally about 40 rpm.

[0058] With the stent rotating in a substantially horizontal plane, the spray nozzle was adjusted so that the distance from the nozzle to the stent was about 2-4 inches and the composition was sprayed substantially horizontally with the brush being directed along the stent from the distal end of the stent to the proximal end and then from the proximal end to the distal end in a sweeping motion at a speed such that one spray cycle occurred in about three stent rotations. Typically a pause of less than one minute, normally about one-half minute, elapsed between layers. Of course, the number of coating layers did and will vary with the particular application. For example, typical tie-layers as at 18 in FIGURE 1, for a coating level of 3-4 mg of heparin per cm^2 of projected area, 20 cycles of coating application are required and about 30 ml of solution will be consumed for a 3.5 mm diameter by 14.5 cm long stent.

[0059] The rotation speed of the motor, of course, can be adjusted as can the viscosity of the composition and the flow rate of the spray nozzle as desired to modify the layered structure. Generally, with the above mixes, the best results have been obtained at rotational speeds in the range of 30-50 rpm and with a spray nozzle flow rate in the range of 4-10 ml of coating composition per minute, depending on the stent size. It is contemplated that a more sophisticated, computer-controlled coating apparatus will successfully automate the process demonstrated as feasible in the laboratory.

[0060] Several applied layers make up what is called the undercoat as at 18. In one process, additional upper undercoat layers, which may be of the same or different composition with respect to bioactive material, the matrix, polymeric materials and crosslinking agent, for example, may be applied as the top layer as at 20. The

application of the top layer follows the same coating procedure as the undercoat with the number and thickness of layers being optional. Of course, the thickness of any layer can be adjusted by adjusting the speed of rotation of the stent and the spraying conditions. Generally, the total coating thickness is controlled by the number of spraying cycles or thin coats which make up the total coat.

[0061] As shown at 22 in FIGURE 1, the coated stent is thereafter subjected to a curing step in which the prepolymer and crosslinking agents cooperate to produce a cured polymer matrix containing the biologically active species. The curing process involves evaporation of the solvent xylene, THF, etc. and the curing and crosslinking of the polymer. Certain silicone materials can be cured at relatively low temperatures, (i.e., RT-50°C) in what is known as a room temperature vulcanization (RTV) process. More typically, however, the curing process involves higher temperature curing materials and the coated stents are put into an oven at approximately 90°C or higher for approximately 16 hours. The temperature may be raised to as high as 150°C for dexamethasone containing coated stents. Of course, the time and temperature may vary with particular silicones, crosslinkers and biologically active species.

[0062] Stents coated and cured in the manner described need to be sterilized prior to packaging for future implantation. For sterilization, gamma radiation is a preferred method particularly for heparin containing coatings; however, it has been found that stents coated and cured according to the process of the invention subjected to gamma sterilization may be too slow to recover their original posture when delivered to a vascular or other lumen site using a catheter unless a pretreatment step as at 24 is first applied to the coated, cured stent.

[0063] The pretreatment step involves an argon plasma treatment of the coated, cured stents in the unconstrained configuration. In accordance with this procedure, the stents are placed in a chamber of a plasma surface treatment system such as a Plasma Science 350 (Himont/Plasma Science, Foster City, CA). The system is equipped with a reactor chamber and RF solid-state generator operating at 13.56 MHz and from 0-500 watts power output and being equipped with a microprocessor controlled system and a complete vacuum pump package. The reaction chamber contains an unimpeded work volume of 16.75 inches (42.55 cm) by 13.5 inches (34.3 cm) by 17.5 inches (44.45 cm) in depth.

[0064] In the plasma process, unconstrained coated stents are placed in a reactor chamber and the system is purged with nitrogen and a vacuum applied to 20-50 mTorr. Thereafter, inert gas (argon, helium or mixture of them) is admitted to the reaction chamber for the plasma treatment. A highly preferred method of operation consists of using argon gas, operating at a power range from 200 to 400 watts, a flow rate of 150-650 standard ml per minute, which is equivalent to 100 - 450

mTorr, and an exposure time from 30 seconds to about 5 minutes. The stents can be removed immediately after the plasma treatment or remain in the argon atmosphere for an additional period of time, typically five minutes.

[0065] After this, as shown at 26, the stents may be exposed to gamma sterilization at 2.5-3.5 Mrad. The radiation may be carried out with the stent in either the radially unconstrained status or in the radially constrained status.

[0066] Preferably, however, the surface is modified prior to plasma treatment or just prior to sterilization by one of several additional processing methods of which some are described in relation to the following examples.

Example 1. Fluorosilicone surface treatment of eluting heparin coating.

[0067] The undercoat of a stent was coated as multiple applied layers as described above thereafter and cured as described at 22. The heparin content of the undercoat was 37.5% and the coating thickness was about 30-40 μ . Fluorosilicone (FSi) spray solution was prepared at 30 from a fluorosilicone suspension (Applied Silicone #40032) by weighing an amount of fluorosilicone suspension and adding tetrahydrofuran (THF) according to the relation equation of $V_{THF} = 1.2 \times$ the weight of fluorosilicone suspension. The solution was stirred very well and spray-coated on the stent at 32 using the technique of the application of the undercoat process at 18 and the coated stents were cured at 90°C for 16 hours. The coated stents are argon plasma treated prior to gamma sterilization according to the procedures described above in accordance with steps 22-26.

[0068] FIGURE 7 is a plot of heparin release kinetics in phosphate buffer system with fluorosilicone topcoat and without any topcoat. The thickness of the topcoat is about 10-15A. While it does not appear on the graph of FIGURE 7, it should be noted that the release rate for the coating without FSi is initially about 25 times higher than that with FSi, i.e., during the first 2 hours. This is, of course, clearly off the scale of the graph. It is noteworthy, however, that the coating with the FSi top layer or diffusion barrier does show a depressed initial release rate combined with an enhanced elution rate after the first day and through the first week up until about the tenth day. In addition, the fluorosilicone (FSi) topcoat, by virtue of the high electronegativity of fluorination maintains non-thrombogenic surface qualities during and after the elution of the biologically active heparin species. In addition, because of the negative charges off the heparin itself, the electronegativity of the fluorosilicone topcoat may be, at least in part, responsible for the modified heparin release kinetic profile.

[0069] FIGURE 8 compares a plot of fluorosilicone (FSi) top coating containing 16.7% imbedded heparin

with one containing fluorosilicone (FSi) only. An undercoating is identical to that utilized in FIGURE 7 containing about 37.5% heparin to a thickness of about 30-40 microns. These elution kinetics are quite comparable with the heparin-free FSi top layer greatly reducing the initial burst of heparin release and otherwise the heparin in the FSi top layer imparts a slightly greater release over the period of the test.

Example 2. Immobilization of polyethylene glycol (PEG) on drug eluting undercoat.

[0070] An undercoat was coated on a stent and cured at 22 as in Example 1. The stent was then treated by argon gas plasma as at 24 and ammonium gas plasma at 40. The equipment and the process of argon gas plasma treatment was as has been described above. The ammonium plasma treatment was implemented immediately after the argon gas plasma treatment, to aminate the surface of the coating. The ammonium flow rate was in the range of 100-700 cubic centimeter per minute (ccM) in preferably in the range of 500-600 ccM. The power output of radio frequency plasma was in the range of 50-500 watts, preferably in ~200 watts. The process time was in the range of 30sec-10min, preferably ~5min.

[0071] Immediately after amination, the stents were immersed into electrophilically activated polyethylene glycol (PEG) solution at 42. PEG is known to be an inhibitor of protein absorption. Examples of electrophilically activated PEG are PEG nitrophenyl carbonates, PEG trichlorophenyl carbonates, PEG tresylate, PEG glycidyl ether, PEG isocyanate, etc., optionally with one end terminated with methoxyl group. Molecular weight of PEG ranged from about 1000-6000, and is preferable about 3000. It has been observed that simple ammonium amination will not generate large quantities of primary and secondary amines on the elastomeric polymer surface (for example silicone). Instead, imine ($>C=N-H$), and other more oxidative nitro containing groups will dominate the surface. It is generally necessary to add reductive agent, such as $NaBH_3CN$ into the reaction media so that the functional group on PEG can react with imine and possibly other nitro-containing species on the surface, and therefore immobilize PEG onto the surface. The typical concentration of $NaBH_3CN$ is about 2mg/ml. Since PEG and its derivatives dissolve in water and many polar and aromatic solvents, the solvent used in the coating must be a solvent for PEG but not for the drug in the undercoat to prevent the possible loss of the drug through leaching. In the case of eluting-heparin coating, a mixed solvent of formamide and methyl ethyl ketone (MEK) or a mixed solvent of formamide and acetone are preferred solvents, (preferably at ratios of 30 formamide: 70 MEK or acetone by volume), since they will not dissolve heparin. The concentration of PEG, the reaction time, the reaction temperature and the pH value depend on the kind of PEG employed. In the case

of eluting heparin coating, 5% PEG tresylate in (30-70) Formamide/MEK was used successfully. The reaction time was 3 hours at room temperature. PEG was then covalently bound to the surface. Gamma radiation was then used for sterilization of this embodiment as previously described.

[0072] With respect to the anticoagulant material heparin, the percentage in the undercoat is nominally from about 30-50% and that of the topcoat from about 0-30% active material. The coating thickness ratio of the topcoat to the undercoat varies from about 1:10 to 1:2 and is preferably in the range of from about 1:6 to 1:3.

[0073] To produce a topcoat which is substantially free of pores, materials such as porosigens, which can be removed or leached out of the topcoat should not be included in the composition used to form the topcoat. One way of preparing a substantially non-porous topcoat is to apply a topcoat composition which comprises substantially pure polymeric materials. These materials preferably impart biocompatibility to the implanted device during and after the release of the biologically active material.

[0074] A topcoat which only partially covers the undercoat can be formed in a number of ways. Such methods include controlling the thickness of the topcoat so that it is less than the diameter of certain drug particles in the undercoat. For example, when a drug used in the undercoat has an average particle size of 5 μm , it is possible that 15% of the particles will be greater than or equal to 8 μm . At the molecular level, the surface unevenness is at least more than 5 microns. By application of a topcoat of about 5 micron or less. The uneven surface will become smooth to a certain degree. But uncovered areas will still exist, which allows water to penetrate into the undercoat, swelling the drug particle, or dissolving the drug. Due to the osmotic pressure, the drug will elute out through the uncovered areas. If the osmotic pressure is too high, cracks or voids may form in the topcoat which allows drugs to elute from the undercoat to the body.

[0075] As illustrated in FIGURE 9, in a coating 102 which covers a surface of a prosthesis 101, a thin topcoat 104 of the coating 102 only partially covers the undercoat 103 of the coating 102. By having the topcoat 104 cover less than the entire surface of the undercoat 103, parts of the undercoat 103, including a number of drug particles 105, are exposed to body fluids at the implantation site so that the drug 105 can be released. By using a topcoat 104 having a thickness which is about the average particle size of the drug 105, certain larger sized drug particles 106 will not be covered by the topcoat 104.

[0076] Other methods to form a partially covered topcoat include using a polymer which is incompatible to the undercoat elastomer as the biocompatible material of the topcoat. Because of the incompatibility between the materials, a microphase separation will form in the topcoat which will leave the undercoat partially uncov-

ered. Persons skilled in the art are aware of suitable combinations of such incompatible materials.

[0077] Another method involves applying a poor solvent wash to the topcoat to force the biocompatible polymer to shrink and create uneven surfaces voids in the topcoat which forms a topcoat which partially covers the undercoat.

[0078] In yet another method of making a topcoat which partly or fully covers the undercoat, topcoat and undercoat materials having different Young's moduli (either before or after they have cured) are used. For instance, a topcoat material having a higher Young's modulus compared to that of the undercoat material can be employed. When the coated device is mounted on the delivery device or during deployment of the coated device, the topcoat undergoes compression or stretching or other types of mechanical challenges. Since the topcoat material has a higher Young's modulus, it will tend to crack and form voids in the topcoat to allow the drug of the undercoat to elute therefrom.

[0079] Another method for forming the topcoat involves using a bioabsorbable material in the topcoat, which can cover the entire undercoat or only a part of the undercoat. When the coated device comes into contact with body fluid, the topcoat begins to degrade either at the surface or throughout the bulk of the topcoat. The rate of degradation depends upon the type of bioabsorbable material used. Once the topcoat has been partially absorbed, the undercoat is exposed to body tissue and the drug in the undercoat is released, but the burst release or effect is reduced.

[0080] Suppressing the burst effect also enables a reduction in the drug loading or in other words, allows a reduction in the coating thickness, since the physician will give a bolus injection of antiplatelet/anticoagulation drugs to the patient during the stenting process. As a result, the drug imbedded in the stent can be fully used without waste. Tailoring the first day release, but maximizing second day and third day release at the thinnest possible coating configuration will reduce the acute or subacute thrombosis particularly if drugs such as heparin are incorporated.

[0081] FIGURE 4 depicts the general effect of drug loading for coatings of similar thickness. The initial elution rate increases with the drug loading as shown in FIGURE 5. The release rate also increases with the thickness of the coating at the same loading but tends to be inversely proportional to the thickness of the topcoat as shown by the same drug loading and similar undercoat thickness in FIGURE 6.

[0082] What is apparent from the data gathered to date, however, is that the process of the present invention enables the drug elution kinetics to be controlled in a manner desired to meet the needs of the particular stent application. In a similar manner, stent coatings can be prepared using a combination of two or more drugs and the drug release sequence and rate controlled. For example, antiproliferation drugs may be combined in the

undercoat and antiplatelet drugs in the topcoat. In this manner, the antiplatelet drugs, for example, heparin, will elute first followed by antiproliferation drugs to better enable safe encapsulation of the implanted stent.

[0083] The heparin concentration measurement were made utilizing a standard curve prepared by complexing azure A dye with dilute solutions of heparin. Sixteen standards were used to compile the standard curve in a well-known manner.

[0084] For the elution test, the stents were immersed in a phosphate buffer solution at pH 7.4 in an incubator at approximately 37°C. Periodic samplings of the solution were processed to determine the amount of heparin eluted. After each sampling, each stent was placed in heparin-free buffer solution.

[0085] As stated above, while the allowable loading of the elastomeric material with heparin may vary, in the case of silicone materials, heparin may exceed 60% of the total weight of the layer. However, the loading generally most advantageously used is in the range from about 10% to 45% of the total weight of the layer. In the case of dexamethasone, the loading may be as high as 50% or more of the total weight of the layer but is preferably in the range of about 0.4% to 45%.

[0086] It will be appreciated that the mechanism of incorporation of the biologically active species into a thin surface coating structure applicable to a metal stent is an important aspect of the present invention. The need for relatively thick-walled polymer elution stents or any membrane overlayers associated with many prior drug elution devices is obviated, as is the need for utilizing biodegradable or reabsorbable vehicles for carrying the biologically active species. The technique clearly enables long-term delivery and minimizes interference with the independent mechanical or therapeutic benefits of the stent itself.

[0087] Coating materials are designed with a particular coating technique, coating/drug combination and drug infusion mechanism in mind. Consideration of the particular form and mechanism of release of the biologically active species in the coating allow the technique to produce superior results. In this manner, delivery of the biologically active species from the coating structure can be tailored to accommodate a variety of applications.

[0088] Whereas the above examples depict coatings having two different drug loadings or percentages of biologically active material to be released, this is by no means limiting with respect to the invention and it is contemplated that any number of layers and combinations of loadings can be employed to achieve a desired release profile. For example, gradual grading and change in the loading of the layers can be utilized in which, for example, higher loadings are used in the inner layers. Also layers can be used which have no drug loadings at all. For example, a pulsatile heparin release system may be achieved by a coating in which alternate layers containing heparin are sandwiched

between unloaded layers of silicone or other materials for a portion of the coating. In other words, the invention allows untold numbers of combinations which result in a great deal of flexibility with respect to controlling the release of biologically active materials with regard to an implanted stent. Each applied layer is typically from approximately 0.5 microns to 15 microns in thickness. The total number of sprayed layers, of course, can vary widely, from less than 10 to more than 50 layers; commonly, 20 to 40 layers are included. The total thickness of the coating can also vary widely, but can generally be, from about 10 to 200 microns.

[0089] Whereas the polymer of the coating may be any compatible biostable elastomeric material capable of being adhered to the stent material as a thin layer, hydrophobic materials are preferred because it has been found that the release of the biologically active species can generally be more predictably controlled with such materials. Preferred materials include silicone rubber elastomers and biostable polyurethanes specifically.

[0090] This invention has been described herein in considerable detail in order to comply with the Patent Statutes and to provide those skilled in the art with the information needed to apply the novel principles and to construct and use embodiments of the example as required. However, it is to be understood that the invention can be carried out by specifically different devices and that various modifications can be accomplished without departing from the scope of the invention itself.

Claims

1. A medical device having at least a portion which is implantable into the body of a patient, wherein at least a part of the device portion is covered with a coating 102 for release of at least one biologically active material 105, wherein said coating 102 comprises an undercoat 103 having an outer surface and comprising a polymeric material incorporating an amount of biologically active material 105 therein for timed release therefrom, and wherein said coating 102 further comprises a topcoat 104 which covers less than the entire outer surface of the undercoat 103, said topcoat 104 comprising a polymeric material substantially free of pores and porosigens.
2. The device of claim 1 wherein the device is a stent for implantation in a vascular lumen comprising a tubular body having open ends and a sidewall, wherein the coating 102 covers at least a part of a surface of said sidewall, and wherein the polymeric material of the topcoat 104 is selected from the group consisting of fluorosilicone and polyethylene glycol (PEG).
3. The device of claim 1 or 2 wherein the topcoat 104 covers less than the entire undercoat 103 while the device is implanted.
4. The device of claim 1 or 2 wherein the topcoat 104 covers less than the entire undercoat 103 before the device is implanted.
5. The device of claim 1 or 2 wherein the topcoat 104 covers less than the entire undercoat 103 before the device is implanted and while the device is implanted.
6. The device of claim 1 or 2 wherein the polymeric material of the undercoat 103 is a hydrophobic elastomeric material and wherein the polymeric material of the topcoat 104 is a biostable, biocompatible material which provides long term non-thrombogenicity to the device portion during and after release of the biologically active material 105.
7. The device of claim 1 or 2 wherein the topcoat 104 reduces a burst release of the biologically active material 105 as compared to a coated device without the topcoat 104.
8. The device of claim 1 or 2 wherein the biologically active material 105 is heparin.
9. The device of claim 1 wherein the polymeric material of the topcoat 104 is selected from the group consisting of fluorosilicone, polyethylene glycol (PEG), polysaccharides, phospholipids and combinations thereof.
10. The device of claim 9 wherein the polymeric material is fluorosilicone.
11. The device of claim 9 wherein the polymeric material is polyethylene glycol (PEG).
12. The device of claim 1 or 2 wherein the topcoat 104 covers from about 5% to 95% of the surface of the undercoat 103.
13. The device of claim 12 wherein the topcoat 104 covers from about 20% to 85% of the surface of the undercoat 103.
14. The device of claim 1 or 2 wherein the topcoat 104 has an average thickness of about 1 to 7 microns.
15. The device of claim 14 wherein the topcoat 104 has an average thickness of about 1 to 5 microns.
16. The device of claim 1 or 2 wherein the topcoat 104 has an average thickness of about the average particle size of the biologically active material 105.

17. The device of claim 1 or 2 wherein the device is an expandable stent.
18. The device of claim 1 or 2 wherein the polymeric materials of the topcoat 104 and the undercoat 103 are water permeable.
19. The stent of claim 2 wherein the stent is selfexpandable and the sidewall comprises at least one opening therein and wherein the coating 102 conforms to said sidewall in a manner that preserves said opening.
20. A method of coating an implantable stent prosthesis having at least a portion which is implantable into the body of a patient, wherein at least a part of the stent portion is covered with a coating 102 for release of at least one biologically active material 105; the method comprising:
 - (a) applying an undercoat 103 comprising a polymeric material and the biologically active material 105 to the stent portion; and
 - (b) applying a topcoat 104 over the surface of the undercoat 103, said topcoat 104 comprising a polymeric material, substantially free of pores and pore-forming materials.
21. The method of claim 20 wherein the polymeric material of the undercoat 103 is a hydrophobic elastomeric material and wherein the polymeric material of the undercoat 103 is a biostable, biocompatible material which provides long term non-thrombogenicity to the stent portion during and after release of the biologically active material 105.
22. The method of claim 20 wherein the polymeric material of the topcoat 104 is selected from the group consisting of fluorosilicone, polyethylene glycol (PEG), polysaccharides, phospholipids and combinations thereof.
23. The method of claim 20 wherein the topcoat 104 covers from about 5% to 95% of the surface of the undercoat 103.
24. The method of claim 23 wherein the topcoat 104 covers from about 20% to 85% of the surface of the undercoat 103.
25. The method of claim 20 wherein the topcoat 104 has an average thickness of about the average particle size of the biologically active material 105.
26. The method of claim 20 wherein the topcoat 104 has an average thickness of about 1 to 7 microns.
27. The method of claim 26 wherein the topcoat 104 has an average thickness of about 1 to 5 microns.
28. The method of claim 20 wherein the polymeric material of the topcoat 104 is a polymer which is incompatible with the polymeric material of the undercoat 103 such that a topcoat 104 covering less than the entire surface of the undercoat 103 is formed.
29. The method of claim 20 which further comprises applying a poor solvent to the topcoat 104 to shrink the polymeric material to form a topcoat 104 which covers less than the entire surface of the undercoat 103.
30. The method of claim 20 wherein the Young's modulus of the polymeric material of the undercoat 103 and the Young's modulus of the polymeric material of the topcoat 104 are different.
31. The method of claim 30 wherein the Young's modulus of the polymeric material of the topcoat 104 is greater than the Young's modulus of the polymeric material of the undercoat 103.
32. A method of using an implantable stent prosthesis comprising:
 - (a) providing an implantable stent prosthesis having at least a portion which is implantable into the body of a patient, wherein at least a part of the device portion is covered with a coating 102 for release of at least one biologically active material 105, wherein said coating 102 comprises an undercoat 103 having an outer surface and comprising a polymeric material incorporating an amount of biologically active material 105 therein for timed release therefrom, and wherein said coating 102 further comprises a topcoat 104 which covers less than the entire outer surface of the undercoat 103 said topcoat 104 comprising a polymeric material substantially free of pores and porosigens;
 - (b) implanting the device into the body of a patient; and
 - (c) allowing the biologically active material 105 to be released such that the topcoat 104 limits the burst release of the biologically active material 105.
33. The method of claim 32 wherein the topcoat 104 remains on the undercoat 103 after release of the biologically active material 105.
34. The method of claim 32 wherein the topcoat 104 covers less than the entire undercoat 103 while the device is implanted.

35. The method of claim 32 wherein the topcoat 104 covers less than the entire undercoat 103 before the device is implanted.
36. The method of claim 32 wherein the topcoat 104 covers less than the entire undercoat 103 before the device is implanted and while the device is implanted. 5
37. The method of claim 32 wherein the polymeric material of the undercoat 103 is a hydrophobic elastomeric material and wherein the polymeric material of the topcoat 104 is a biostable, biocompatible material which provides long term non-thrombogenicity to the stent portion during and after release of the biologically active material 105. 10 15
38. The method of claim 32 wherein the polymeric material of the topcoat 104 is selected from the group consisting of fluorosilicone, polyethylene glycol (PEG), polysaccharides, phospholipids and combinations thereof. 20
39. The method of claim 32 wherein the topcoat 104 covers from about 5% to 95% of the surface of the undercoat 103. 25
40. The method of claim 32 wherein the topcoat 104 has an average thickness of about the average particle size of the biologically active material 105. 30
41. The method of claim 32 wherein the topcoat 104 has an average thickness of about 1 to 7 microns.

35


40


45

50


55

Figure 1







- Tie Layer = 37.5% Hep coating, top layer = silicone
- Tie Layer = 37.5% Hep coating, top layer = 16.7% Hep coating
- Single Layer = 37.5% Hep coating



- Tie Layer = 37.5% Hep coating, top layer = silicone
- Tie Layer = 37.5% Hep coating, top layer = 16.7% Hep coating








Figure 7. W or w/o fluorosilicone (FSI) top coat

Note: release rate for the coating w/o FSI is 25 times higher than w/FSI at the first two hrs (not plotted)





Figure 8. Comparison of fluorosilicone (FSI) top coat w or w/o heparin. The thickness of the tie coat (37.5%) heparin is about 40 micron.






FIG. 9



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 923 953 A3**

(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3:
29.11.2000 Bulletin 2000/48

(51) Int. Cl.⁷: **A61L 31/00**

(43) Date of publication A2:
23.06.1999 Bulletin 1999/25

(21) Application number: **98202050.5**

(22) Date of filing: **19.06.1998**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(72) Inventors:
• **Ding, Ni**
Plymouth, Minnesota 55446 (US)
• **Helmus, Michael N.**
Long Beach, California 90807 (US)

(30) Priority: **22.12.1997 US 996410**

(71) Applicant: **SCHNEIDER (USA) INC.**
Plymouth, Minnesota 55442 (US)

(74) Representative:
Horner, Martin Grenville et al
Cruikshank & Fairweather
19 Royal Exchange Square
Glasgow G1 3AE Scotland (GB)

(54) **Drug coating with topcoat**

(57) A coating and method for a coating an implantable device or prostheses are disclosed. The coating includes an undercoat of polymeric material containing an amount of biologically active material, particularly heparin, dispersed therein. The coating further includes a topcoat which covers less than the entire surface of the undercoat and wherein the topcoat comprises a poly-

meric material substantially free of pores and porogens. The polymeric material of the topcoat can be a biostable, biocompatible material which provides long term non-thrombogenicity to the device portion during and after release of the biologically active material.




FIG. 9

EP 0 923 953 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

Application Number

EP 98 20 2050

DOCUMENTS CONSIDERED TO BE RELEVANT			Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages			
X,D	CA 2 207 659 A (SCHNEIDER USA INC) 13 December 1997 (1997-12-13) * the whole document *	1-28, 30-41	A61L31/00	
X	WO 97 10011 A (SCHNEIDER USA INC) 20 March 1997 (1997-03-20) * page 20, line 20 - page 21, line 9 * * page 12, line 15 - page 13, line 2 * * page 24, line 14 - page 25, line 9 * * figures *	1-10, 12-28, 30-41		
X	US 5 447 724 A (RALEIGH CAROL L ET AL) 5 September 1995 (1995-09-05) * column 1, line 35 - column 2, line 51 * * column 5, line 38 - line 53 *	1,3,20		
X	WO 92 15286 A (SHIKANI ALAIN ;NOVA PHARM CORP (US)) 17 September 1992 (1992-09-17) * examples 2,3 *	1,20		
A	US 5 624 411 A (TUCH RONALD J) 29 April 1997 (1997-04-29) * column 2, line 23 - column 3, line 26 *	1-41	TECHNICAL FIELDS SEARCHED (Int.Cl.6)	
				A61L
INCOMPLETE SEARCH <p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claims 32-41 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the composition.</p>				
Place of search		Date of completion of the search		Examiner
THE HAGUE		27 September 2000		Muñoz, M
CATEGORY OF CITED DOCUMENTS <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>				

EPO FORM 1503 03.82 (P4/C07)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 98 20 2050

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

27-09-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
CA 2207659 A	13-12-1997	EP 0832655 A	01-04-1998
		JP 10052502 A	24-02-1998
		US 6099562 A	08-08-2000
WO 9710011 A	20-03-1997	US 5837313 A	17-11-1998
		AU 703805 B	01-04-1999
		AU 6965296 A	01-04-1997
		BR 9610607 A	04-05-1999
		EP 1019107 A	19-07-2000
		JP 11500047 T	06-01-1999
		NO 981066 A	08-05-1998
US 5447724 A	05-09-1995	US 5569463 A	29-10-1996
		AU 7998091 A	10-12-1991
		WO 9117724 A	28-11-1991
WO 9215286 A	17-09-1992	AU 1579092 A	06-10-1992
		US 5437656 A	01-08-1995
		US 5344411 A	06-09-1994
		US 5512055 A	30-04-1996
		US 5762638 A	09-06-1998
		US 5695458 A	09-12-1997
US 5624411 A	29-04-1997	US 5464650 A	07-11-1995
		EP 0623354 A	09-11-1994
		JP 8033718 A	06-02-1996
		US 5837008 A	17-11-1998
		US 5679400 A	21-10-1997
		US 5776184 A	07-07-1998
		US 5824048 A	20-10-1998

EPO FORM P439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)